Your browser doesn't support javascript.
loading
The impact of vacuum-assisted excision in the management of indeterminate B3 lesions in the NHS Breast Screening Programme in England.
Sharma, N; Cornford, E; Cheung, S; Price, H; Kearins, O.
Afiliación
  • Sharma N; Breast Unit, Seacroft Hospital, York Road, Leeds LS146UH, UK. Electronic address: Nisha.sharma2@nhs.net.
  • Cornford E; Thirlestaine Breast Unit, Cobalt House, Gloucestershire Hospitals Foundation Trust, Thirlestaine Road, Cheltenham, Gloucestershire GL53 7AS, UK.
  • Cheung S; Public Health England, 5 St Philips Place, Birmingham B3 2PW, UK.
  • Price H; Public Health England, 5 St Philips Place, Birmingham B3 2PW, UK.
  • Kearins O; Screening Division, Health Improvement Directorate, Public Health England, 5 St Philips Place, Birmingham B3 2PW, UK.
Clin Radiol ; 76(6): 470.e23-470.e29, 2021 Jun.
Article en En | MEDLINE | ID: mdl-33814122
ABSTRACT

AIM:

To assess the impact of vacuum-assisted excision (VAE) on the management of B3 lesions in the England NHS Breast Screening Programme following an update of national guidance. A secondary aim was to investigate the histological features of malignancies resulting from upgrade of B3 lesions by either VAE or surgery. MATERIALS AND

METHODS:

The study population was all women recalled for assessment after breast screening who had a wide-bore needle biopsy with a B3 result over the period 01/04/2018 to 31/03/2019. Data were extracted from the National Breast Screening Service (NBSS) computer system at unit level. Women with a B3 result were split into those with and without atypia. The upgrade rates and histological features of malignancies in the different groups were analysed.

RESULTS:

In total, 2,234,514 women attended for screening between 1/4/218 and 31/3/2019, 84,559 women were referred to assessment, and of those 40,037 women had a core biopsy resulting in 3,355 were B3 lesions (8.38%). Within these, 556 cancers were diagnosed, giving an upgrade rate of 16.57% (556/3,355). The upgrade for B3 lesions with atypia was significantly higher than for B3 lesions without atypia (29.1% versus 13.3%, p<0.001).

CONCLUSION:

The introduction of the new B3 guidelines has resulted in 73.8% of B3 lesions with atypia and 65.1% of B3 lesions with no atypia having VAE rather than surgery. The data highlights the importance of managing these indeterminate lesions appropriately with an overall upgrade rate of 16.57%.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Límite: Female / Humans País/Región como asunto: Europa Idioma: En Revista: Clin Radiol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Diagnostic_studies / Guideline / Screening_studies Límite: Female / Humans País/Región como asunto: Europa Idioma: En Revista: Clin Radiol Año: 2021 Tipo del documento: Article
...